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Objective: To develop a long-term prediction model
of first major cardiovascular event and to assess its
clinical utility in a low-incidence European population.
Setting: Four independent population-based cohorts
enrolled between 1986 and 1993 in Northern Italy.
Participants and methods: N=5247 35-year-old to
69-year-old men and women free of cardiovascular
disease at baseline. Absolute 20-year risk of first fatal
or non-fatal coronary or ischaemic stroke event
(monitoring trends and determinants in cardiovascular
disease (MONICA) validated) was estimated from
gender-specific Cox models.
Main outcome measures: Model discrimination
(area under the receiver operating characteristic (ROC)-
curve, AUC). ‘High-risk’ subjects were identified based
on several threshold values for the 20-year predicted
risk. Clinical utility was defined in terms of fraction of
missed events (events among those considered at low-
risk) and unnecessary treatment (false:true positive
ratio). A net benefit curve was also provided.
Results: Kaplan-Meier 20-year risk was 16.1% in men
(315 events) and 6.1% in women (123 events). Model
discrimination (AUC=0.737 in men, 0.801 in women)
did not change significantly as compared to 10-year
prediction time interval. In men, with respect to risk
stratification based on the number of risk factors, a
20% predicted risk cut-off would miss less events
(36% vs 50%) and reduce unnecessary treatment
(false:true positive ratio 2.2 vs 3.0); the net benefit
was higher over the whole range of threshold values.
Similar considerations hold for women.
Conclusions: Long-term prediction has good
discrimination ability and is clinically useful for risk
stratification in primary prevention. A clinical utility
analysis is recommended to identify the optimal
stratification according to different public health goals.
INTRODUCTION
Current European and American guidelines
for the primary prevention of major coronary
and stroke events recommend the use of a
multivariable risk prediction model to iden-
tify high-risk subjects.1 2 Several risk scores are
available in different US3 4 and European5
populations of middle-aged adults, including
the Italian one,6 to estimate the risk of first
fatal and non-fatal cardiovascular event over a
10-year time interval. Primary prevention,
however, has been recently moved towards
the concepts of ‘lifetime’7 and ‘long-term’
risks,8 motivated also by the increasing life
expectancy in western countries. To this
extent, 10-year risk prediction models are
inadequate to distinguish between those at
both low short-term and long-term risks, and
those at low short-term but at elevated long-
term risk due to the presence of non-optimal
risk factors levels.9–11 In the Framingham
Study population, an unfavourable risk factor
profile led to an increased 30-year risk of first
cardiovascular event, independently on the
age at the risk factors assessment.10 In a repre-
sentative sample of the Italian population,
about 80% of individuals classified at low
10-year risk had increased lifetime risk
according to US definition (≥40%), poten-
tially leading to a consistent number of unpre-
vented events that might have been prevented
if lifetime risk had been considered.11 This
group was largely composed of women and
young individuals suggesting that long-term
prediction models for risk stratification may
be even more beneficial in populations at low
incidence of cardiovascular disease (CVD).12
To this extent, the development of a specific
long-term risk prediction should be preferred
with respect to recalibration of risk models
derived in high-incidence countries.13
However, extending the range of risk predic-
tion is not a straightforward operation.
Although several studies have shown that a
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single measurement of risk factor is predictive of future
events after 30 plus years,10 14 behavioural changes and
risk factors modification may affect model discrimination.
High-quality follow-up data, with a consistent event defin-
ition and validation over time, are also required. Finally,
subjects’ stratification in risk categories is often based on
arbitrary cut-points of absolute risk15 which may show no
benefit in clinical practice.16 The evaluation of the clin-
ical benefit of long-term prediction by means of some
standard measure17 has not been provided so far and is
therefore required.18
The aim of the present article is to develop a 20-year
risk score equation in a European population of men
and women considered at low incidence of major cardio-
vascular events. In addition to standard model calibra-
tion and discrimination tools, we evaluate the clinical
utility of the model for risk stratification.
METHODS
Study population
The Brianza population comprises residents in 173
municipalities in the area between Milan and the Swiss
border, Northern Italy. The CAMUNI (CArdiovascular
Monitoring Unit in Northern Italy) study includes four
independent population surveys carried out between
1986 and 1994 as part of either the WHO MONItoring
of trends and determinants in CArdiovascular disease
(MONICA) Project (3 surveys; 18) or the Pressioni
Arteriose Monitorate E Loro Associazioni (PAMELA)
study.19 Participation rates were 70.1%, 67.2% and
70.8% for the three MONICA surveys, respectively, and
64% for the PAMELA Study, with no differences
between men and women. The baseline screening as
well as the follow-up for all the surveys were approved by
the ethical committee of the Monza Hospital.
Baseline assessment of risk factors
Cardiovascular risk factors were collected at baseline
strictly adhering to the standardised procedures and
quality standards of the WHO-MONICA Project.20
Height and weight were measured on participants
without shoes and wearing light clothing. Trained tech-
nicians collected blood pressure at right arm on partici-
pants in sitting position and at rest, using a standard
mercury sphygmomanometer equipped with two side
cuff bladders, for normal and obese participants.
Systolic and diastolic blood pressures were assessed
twice, at 5 min apart, recording the first and fifth phase
of the Korotkoff sounds. The study variable for systolic
blood pressure is the average of the two measurements.
Venous blood specimens were taken from the antecubi-
tal vein on fasting participants (12 h or more). Serum
total cholesterol, high-density lipoprotein
(HDL)-cholesterol and blood glucose were determined
using the enzymatic methods; HDL-cholesterol fraction
was separated using the phosphotungstate-Mg++
method.20 A standardised interview was administered to
participants by trained interviewers. Information on the
use of antihypertensive treatment in the last 2 weeks was
dichotomised as yes/no; similarly, cigarette smoking
habit was dichotomised as current versus past/never
smokers. Diabetes mellitus was defined using self-
reported diagnoses, information on insulin and oral
hypoglycaemic treatments and fasting blood glucose
exceeding 7 mmol/L (126 mg/dL). The presence at
baseline of a previous history of myocardial infarction
(MI), unstable angina pectoris, cardiac revascularisation
or stroke was defined based on self-reported
information.
Study endpoint and follow-up procedures
The study endpoint is defined as the occurrence of first
major coronary event (MI, acute coronary syndrome
and coronary revascularisation) as well as for first ischae-
mic stroke or carotid endarterectomy, fatal and non-
fatal.13 Data completeness for fatal events was assured
through a systematic collection of death certificates pro-
vided by local health units; vital status and death certifi-
cates were available for 99% of the participants.
Suspected out-of-hospital deaths were investigated
through interviewing relatives. Suspected hospitalised
coronary (International Classification of Diseases 9th
edition (ICD-9) discharge code 410 or 411 and ICD-9
Clinical Modification (CM) 36.0–9 for coronary revascu-
larisation) and stroke events (ICD-9 430–432, 434, 436;
ICD-9 CM 38.01–39.22 or 39.50–39.52 with at least one
430–438 as discharge code, for carotid endarterectomy)
were identified through deterministic and probabilistic
record linkages with regional hospital discharge data-
bases, obtaining a satisfactory performance in case
finding, as reported.18 21 All acute events were investi-
gated and validated according to the MONICA diagnos-
tic criteria20; the ischaemic subtype for stroke was
attributed after review of the available clinical
information.
Statistical analysis
Our 20-year risk prediction model is based on gender-
specific Cox regression models with age, total cholesterol,
HDL-cholesterol, systolic blood pressure, antihyperten-
sive treatment, cigarette smoking and diabetes. These
predictors are core risk factors included in the CUORE
Project6 13 as well as in other 10-year risk equations.3 4
After a preliminary check on linearity, total cholesterol
and HDL-cholesterol were included in the model as
categorical variables in four standard classes.4 22 The
interaction between systolic blood pressure and antihy-
pertensive treatment was not statistically significant (p
value=0.84 in men and 0.12 in women, respectively).
There was no evidence of any cohort effect in the full
model, in men (3df test p value=0.2) nor in women
(p value=0.5). Finally, no violations in the proportional
hazard assumption were observed using a standard test
for time-dependent variables.
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Model calibration was assessed through the
Grønnesby-Bogan goodness-of-fit test.23 The area under
the receiver operating characteristic (ROC) curve
(AUC), as well as sensitivity and specificity in the top
and bottom predicted risk quintiles, were computed
taking censorship into account.24 Correction for over-
optimism and CIs for the AUC were obtained through
1000 bootstrapped samples.25 To assess the hypothesis of
a loss in discrimination ability due to a longer prediction
period, we estimated the 10-year predicted probability of
events in our database, using the same set of risk factors
but with shorter follow-up period, that is, up to the end
of 2002 for all the participants (number of events 234 in
men, 79 in women). We then compared the AUC of the
two models by looking at their respective bootstrapped
CIs. To assess the clinical utility of the long-term model
for risk stratification, we considered two different public
health goals. One is to decrease the number of events
occurring among those considered at ‘low risk’. If we
assume that a subject classified at ‘high risk’ will be tar-
geted for prevention (either lifestyle intervention or
treatment), any event occurring outside this category is
‘not-identified’ or ‘missed’ by the prevention strategy.
The second strategy aims instead to reduce unnecessary
treatment, by decreasing the number of non-events
among those considered at ‘high risk’. Under the two
scenarios, ‘high-risk’ subjects are defined as those with
predicted risk above a certain cut-off value. Clinical
utility is defined in terms of: (1) fraction of ‘missed’
events; (2) probability of event among those classified at
high risk and (3) false positive/true positive ratio, for
several threshold values in the 20-year predicted risk. We
also provide a decision curve analysis based on the net
benefit—Net benefit=(true positives−w×false positives)/
n, where n is the sample size and the weight w repre-
sents the ratio between the harm of unnecessary treat-
ment and the harm of missing a case at that given value
of predicted risk.17 All the analyses were conducted
using the SAS software V.9.2.
RESULTS
N=5426 (2703 men) participants were enrolled in the
age range 35–69 years. N=205 participants (3.8%; n=14
events) had at least one missing data; we considered
data imputation (R transcan function26) and excluded
only those with missing values in more than four covari-
ates of interest (n=6 men and n=3 women). Finally
n=120 men and n=45 women with a positive history of
CVD at baseline were also excluded, reducing the
sample size to 2574 men and 2673 women.
Baseline characteristics of the study population, by
gender, are shown in table 1. During a median follow-up
time of 15 years (IQR 12–20), we observed 315 first CVD
events in men (233 coronary events) and 123 in women
(n=85 coronary events). The Kaplan-Meier estimate for
20-year risk was 16.1% and 6.1% in men and women,
respectively.
Model development
The β-coefficients for the 20-year risk prediction model,
as well as the baseline survival term and the calibration
slope,25 are provided in the online supplementary table
S1. All the risk factors were statistically significant, except
for antihypertensive treatment, though its point estimate
reflected a 30% increase in hazard in men as well as
women; the variable was retained in the model for com-
parability with the short-term CUORE model.6 There
were no significant differences in the set of β estimates
for the 20-year model as compared to those from the
10-year risk model for the risk factors in the model
(data not shown). The model calibration was satisfactory,
in men (Grønnesby-Bogan goodness-of-fit χ2 6.7,
p value=0.67) and in women (χ2 9.6, p=value 0.38); cali-
bration plots are available as online supplementary figure S1.
We found no statistically significant difference in the
overall discrimination ability between long-term and
short-term prediction models, in men (0.736 vs 0.731)
and in women (0.801 vs 0.816; table 2). Only 5% of
20-year events in men occurred among subjects with a
predicted risk below the 20th centile (bottom fifth); the
corresponding figure in women is 2%. The relative risk
of event for being above the 80th centile versus below
the 20th centile of 20-year risk was 9.5 (ie, 35.1/3.7) in
men and 22.4 (ie, 20.2/0.9) in women. Finally, the value
of the 80th centile for 20-year risk was more than twice
as high than the similar percentile for 10-year risk in
men (26.8 vs 10.8) and more than three times as high in
women (10.1 vs 3.0). A similar consideration holds for
the 20th centile of risk or the median value.
Clinical utility
Tables 3 and 4 describe strategies for the identification
of high-risk subjects, based on predicted 20-year risk, in
Table 1 Baseline characteristics (mean (SD) or %) of the





Age (years) 50.8 (9.1) 50.3 (9)
Years of schooling 8.5 (4.2) 7.3 (3.4)
Total cholesterol (mmol/L) 5.8 (1.1) 5.8 (1.1)
HDL-cholesterol (mmol/L) 1.3 (0.3) 1.6 (0.4)
Body mass index (kg/m2) 26.2 (3.5) 25.6 (4.7)
Systolic blood pressure (mm Hg) 134.8 (19.3) 131.6 (20.2)
Diastolic blood pressure (mm Hg) 85.9 (10.6) 82.8 (10.8)
Antihypertensive treatment (%) 11.8 16.0
Fasting plasma glucose (mmol/L) 5.4 (1.3) 5.1 (1.2)
Diabetes (%) 6.7 4.0
Current smoker (%) 37.1 19.6
Incident coronary event (n) 233 85
Incident ischaemic strokes (n) 99 43
Incident CVD event (n) 315 123
20-year absolute risk of CVD* 16.1 6.1
Men and women, 35–69 years, CVD-free at baseline.
*Kaplan-Meier estimate.
CVD, cardiovascular disease; HDL, high-density lipoprotein.
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men and women, respectively. A cut-off value of 10%
20-year risk in men would result in 9% of ‘missed’
events (ie, events among those with predicted risk below
the cut-point), with a probability of event of 23% and 1
true-positive for every 3.4 false-positives. (table 3). In the
second scenario, by choosing the 20% 20-year risk
threshold value, the fraction of missed events was 36%.
Note that about 30% of events occurred for a predicted
20-year risk between 20% and 30%. Finally, using the
number of risk factors to define high-risk would result in
a higher fraction of missed events, with no changes in
specificity or in the prevalence of subjects at high risk.
Among women, a cut-off value of 2% would result in a
5% of missed events, with a probability of event of 9%
and a true-positive for every 10.1 false-positive women
(table 4). In the second scenario, the probability of
event among those with absolute risk greater than 10%
was 20.4%, with a true-positive for every 3.9 false-posi-
tives. However, the fraction of missed events would be
32%; this number can be reduced by lowering the
cut-off value to 8%. By considering at high risk those
with two or more risk factor would result in a higher
fraction of missed events, with no gain in specificity or
in the probability of event in the group. Figure 1 illus-
trates the decision curve analysis based on the net
benefit,17 for men (left) and women (right). The figure
suggests a greater net benefit for the predicted risk with
respect to the number of risk factors over the whole
range of values, thus generalising the findings from
tables 3 and 4.
DISCUSSION
In this article we present the 20-year prediction model
of first major coronary or ischaemic stroke event in a
Northern Italian population aged 35–69 years at
baseline. To our knowledge, this is the first long-term
prediction model in a low-incidence, European popula-
tion. The discrimination ability of the long-term model
did not significantly drop with respect to a 10-year risk
prediction model derived on the same population. Risk
stratification based on the predicted 20-year risk can be
modulated according to different prevention aims, that
is, either to reduce the fraction of events potentially
unprevented or to avoid unnecessary treatment. Under
both scenarios, the predicted 20-year risk showed an
overall better net benefit with respect to a risk stratifica-
tion based on the number of risk factors.
Our data confirmed previous findings on predictiveness
of a single measurement of risk factors on long-term CVD
risk, in the Italian27 as well as in other populations.10 14
Event discrimination for the 20-year risk prediction model
did not change significantly from 10-years, although in
women it decreased from 0.814 to 0.801. In the
Framingham Offspring Study updating the baseline meas-
urement of blood pressure and lipids with a later assess-
ment poorly affected model discrimination and
reclassification28 and cardiometabolic risk factors cluster-
ing has been found to be quite stable over time.29
As in the Framingham population, in our study the
long-term predicted risk was more than simply n-times
the short-term risk prediction.10 In addition in the age
range 35–49 years, the long-term predicted risk in sub-
jects with one or more non-optimal or elevated risk
factors (defined as in Ref. 7) was three times the short-
term risk in men and four times in women (see online
supplementary figure S2). This conveys the importance
of long-term prediction for early identification of young
subjects and women at increased likelihood of the event
during their remaining lifespan. We observed in our
data a modest net reclassification improvement (com-
puted as in24) for the 20-year risk prediction model over
Table 2 Discrimination ability for the 10-year and the 20-year risk prediction models
Men Women
10-year risk 20-year risk 10-year risk 20-year risk
AUC (95% CI) 0.731 (0.702 to 0.761) 0.737 (0.713 to 0.764) 0.814 (0.779 to 0.853) 0.801 (0.771 to 0.833)
Subjects with predicted risk below the 20th centile
20th centile of risk 2.3 6.3 0.3 1.1
Fraction of events* (%) 4.4 5.1 1.4 2.0
Probability of event in
the group† (%)
0.8 3.7 0.2 0.9
Subjects with predicted risk above the 80th centile
80th centile of risk 10.8 26.8 3.0 10.1
Sensitivity* (%) 49.9 45.6 68.7 62.0
Specificity (%) 82.4 85.5 81.1 83.1
Probability of event in
the group† (%)
19.4 35.1 7.5 20.2
Men and women, 35–69 years, CVD-free at baseline.
AUC was estimated taking censorship into account, and adjusting for over-optimism (n=1000 bootstrap).
*Probability of belonging to the group, given that the person is a case.
†Kaplan-Meier estimate of the probability of event in the group.
AUC, area under the receiver operating characteristic (ROC) curve.
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the recalibrated 10-year risk, in men (1.8%) and in
women (4.5%). The net reclassification increased
when we considered subjects with a low 10-year pre-
dicted risk but a cluster of two or more risk factors
(5.4% and 7.6% in men and women, respectively; data
not shown).
Subjects’ stratification is often based on arbitrarily chosen
thresholds of predicted risk,15 which may limit the clinical
utility of risk prediction models.16 We considered two strat-
egies for the identification of ‘high-risk’ subjects with con-
trasting goals, either to decrease the fraction of missed events
or to decrease unnecessary treatment. These can be imple-
mented by choosing threshold values for the predicted risk
driven by either sensitivity or by specificity, respectively.
Despite the lowering costs of statin treatment with respect to
the costs of one unprevented event, the high sensitivity
scenario was not cost-effective over a 10-year period.30 These
two scenarios might be combined to adopt a more complex
risk stratification, as often present in clinical practice.1 2 12
For instance, if we consider at ‘low risk’ the 36% of men with
20-year absolute risk less than 10%, the fraction of missed
events would be 9%, that is, 31 first events in 20 years. About
31% of men with absolute risk between 10% and 20% could
be addressed for lifestyle modification or treatment accord-
ing to the presence of specific risk factors; this category
accounts for about 25% of cases. Finally, 33% of men with
predicted risk above the 20% could be targeted with treat-
ment intervention; they account for 65% of events, and of
3.2 treated men, one is a case. A similar stratification can be
provided for women, with different threshold values reflect-
ing gender-specific underlying risk as for the cardiovascular
age assessment.15
Table 4 Identification of high-risk women based on the 20-year risk prediction model with respect to the number of risk





events (%) Specificity (%) Probability of event* (%) FP/TP ration %
Strategy a: reduce the fraction of missed events
All 2673 100.0 0.0 – 6.1 15.3
1+ Major risk factor† 1654 61.9 17.7 40.1 8.2 11.3
20-year absolute risk >2% 1733 64.8 4.5 37.4 9.0 10.1
20-year absolute risk >5% 1067 39.9 14.7 63.2 13.1 6.6
Strategy b: reduce unnecessary treatment
2+major risk factors† 640 23.9 42.3 79.5 14.8 5.8
20-year absolute risk >8% 698 26.1 22.7 77.1 18.2 4.5
20-year absolute risk >10% 545 20.4 32.1 82.7 20.4 3.9
Women, 35–69 years, CVD-free at baseline.
‘Missed’ events are events occurring among women not classified at ‘high risk’, that is, with 20-year absolute risk (or a number of risk factors)
below the cut-off point.
*Kaplan-Meier estimate of the probability of event in the group (positive predicted value).
†Total cholesterol >240 mg/dL; HDL-cholesterol <50 mg/dL; systolic blood pressure >160 mm Hg; smoking; diabetes. CVD, cardiovascular
disease; FP, number of false positives; HDL, high-density lipoprotein; TP, number of true positives.
Table 3 Identification of high-risk men based on the 20-year risk prediction model with respect to the number of risk factors,





events (%) Specificity (%)
Probability
of event* (%) FP/TP ration %
Strategy a: reduce the fraction of missed events
All 2574 100.0 0.0 – 16.1 5.2
1+ Major risk factor† 1842 71.6 13.7 32.5 19.5 4.1
20-year absolute risk >10% 1645 63.9 9.1 41.2 22.9 3.4
20-year absolute risk >15% 1169 45.4 22.1 60.9 27.7 2.6
Strategy b: reduce unnecessary treatment
2+ Major risk factors† 828 32.2 50.4 73.6 24.9 3.0
20-year absolute risk >20% 841 32.7 35.7 73.7 31.7 2.2
20-year absolute risk >30% 415 16.1 62.6 88.9 37.4 1.7
Men, 35–69 years, CVD-free at baseline.
‘Missed’ events are events occurring among men not classified at ‘high risk’, that is, with 20-year absolute risk (or a number of risk factors)
below the cut-off point.
*Kaplan-Meier estimate of the probability of event in the group (positive predicted value).
†Total cholesterol >240 mg/dL; HDL-cholesterol <40 mg/dL; systolic blood pressure >160 mm Hg; smoking; diabetes.
CVD, cardiovascular disease; FP, number of false positives; HDL, high-density lipoprotein; TP, number of true positives.
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Among the study strengths and limitations, our sample
comprises participants drawn from a representative north-
ern Italian population, with a satisfactory participation rate.
The underlying population is characterised by high levels of
industrialisation and urbanisation, with one of the highest
average incomes in Italy. A major limitation is the lack of an
external validation. External validation for long-term pre-
diction models is in general an issue10; we provide the over-
optimism adjusted AUC as well as the calibration slope25 to
allow applying our equation to different contexts (see
online supplementary material). We also mention high
quality of follow-up procedures, including case ascertain-
ment for non-fatal events21 and a consistent event validation
according to MONICA criteria, resulting in a Standardized
Incidence Rate for the study cohorts above 1 over the whole
follow-up period.18 Finally, the study endpoint reflects the
clinical need to treat the ‘global’ ischaemic risk of a given
patient, and not its separate components.3
In conclusions, we provide a model to predict long-
term risk of first major ischaemic cardiovascular event in
a low-incidence population. Risk stratification based on
long-term risk can be clinically useful, especially for
young individuals and women. A clinical utility analysis
is required to identify the optimal stratification, accord-
ing to different public health goals.
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